Navigation Links
QLT reports initial proof of concept data for punctal plug delivery technology
Date:5/12/2008

oday are an early indication that QLT's drug elution technology has the potential to provide a meaningful therapeutic benefit. To generate proof of concept data for the Company's proprietary punctal plug drug delivery system, QLT is currently enrolling patients in the CORE study, a Phase 2, randomized, double blind trial to assess the safety and efficacy of its latanoprost punctal plug delivery system for the treatment of glaucoma and ocular hypertension at three different doses (low, medium, high). The medium dose of latanoprost in the CORE Study was used in the trial that is being reported today.

About QLT

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne(R) and Eligard(R) and future product opportunities. For more information, visit our web site at http://www.qltinc.com.

QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc.

Atrigel is a registered trademark of QLT USA, Inc.

Visudyne is a registered trademark of Novartis AG.

Eligard is a registered trademark of Sanofi-aventis.

QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."

Certain statements contained in this press release, which are not historical facts, are "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements include, but are not limited to: our beliefs re
'/>"/>

SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Neurobiological Technologies Reports Third Quarter Financial Results
2. Bionovo Reports First Quarter 2008 Financial Results
3. WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting
4. Cardium Reports on First Quarter 2008 Highlights and Financial Results
5. Novavax Reports First Quarter 2008 Financial Results
6. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
7. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
8. Pharmos Corporation Reports 2008 First Quarter Results
9. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
10. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
11. Favrille Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Edison Investment Research, ... the initiation of full coverage of BioAlliance ... and marketing products for orphan oncology and ... (Logo: http://photos.prnewswire.com/prnh/20130417/608168) Edison has today ... merits of BioAlliance Pharma, focusing in particular ...
(Date:6/18/2013)... Toronto, Canada (PRWEB) June 18, 2013 ... FDA oversight of pharmaceutical advertising and promotion, and ... , Viewers will learn how to apply these ... enforcement examples:, ,     The fundamentals on ... advertising and promotional labeling ,     Assessing traditional ...
(Date:6/18/2013)... , June 18, 2013 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/cmbgcv/north_american ) has announced the ... Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market ... Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] ... 2017" report to their offering. ...
(Date:6/18/2013)... June 18, 2013 Earlier this year, Google ... platform. As this directly impacts the core component of ... one of the most sweeping updates since its inception in ... Technologies recently posted a very informative article on ... ‘must-have’ upgrade date for enhanced campaigns . Only ...
Breaking Biology Technology:Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 3Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 2Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 3
... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), ... today announced that it has received clearance ... to begin marketing additional,diameters of its Quill(TM) ... The Quill(TM) SRS PDO is a longer-lasting ...
... fraught with,flare-ups of pain, or breakthrough pain, may ... new easy-to-use oral drug delivery system developed by,BioDelivery ... Cancer patients frequently experience two types of pain: ... continuous pain,present for long periods of time, and ...
... the Fourth ... Quarter, FRAZER, ... a 12-week, Phase 3 clinical,trial of FENTORA(R) (fentanyl buccal tablet) [C-II] in ... The study achieved statistical significance on the primary,endpoint. Results across the 12 ...
Cached Biology Technology:Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 2Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 3Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 4Novel Technology Breaks Through Cancer Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 4Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 5
(Date:6/18/2013)... Research Council, Laboratory of Molecular Biology, has been ... Young Investigator Award. Torrent is being recognized for ... algorithm to predict antimicrobial regions in proteins. Luis ... now applying this algorithm to interrogate full genomes ... with very appealing results." , Torrent obtained ...
(Date:6/18/2013)... The herbal extract of a yellow-flowered mountain plant long ... lifespan of fruit fly populations by an average of ... it,s how Rhodiola rosea , also ... attention of study leaders Mahtab Jafari and Sam Schriner. ... manner completely unrelated to dietary restriction and affects different ...
(Date:6/18/2013)... shows that weight gain and increased head size in the first ... at early school age. , The study was led by University ... 13,800 children who were born full-term. , The results, published in ... put on 40% of their birthweight in the first four weeks ... six years of age, compared with babies who only put on ...
Breaking Biology News(10 mins):The American Society for Microbiology honors Marc Torrent 2Herbal extract boosts fruit fly lifespan by nearly 25 percent, UCI study finds 2IQ link to baby's weight gain in first month 2
... announce 7.5 million of funding for a series of projects ... H1N1 2009 or ,swine flu,. The research will look ... pig and human populations, and in hospital intensive care units. ... reported in Mexico in March this year. In June, as ...
... researchers from Carnegie Mellon University, Goettingen Medical School in ... Kingdom have received a Human Frontiers Science Program (HFSP) ... better understand the "cellular GPS" system that guides neurons ... In the course of the development and repair of ...
... CORVALLIS, Ore. - Penguins that died 44,000 years ago ... challenge the accuracy of traditional genetic aging measurements, and ... of many specimens by 200 to 600 percent. ... DNA testing to be 100,000 years old may actually ...
Cached Biology News:£7.5 million ($12.6 million) collaborations lead UK research community's response to H1N1 pandemic 2£7.5 million ($12.6 million) collaborations lead UK research community's response to H1N1 pandemic 3£7.5 million ($12.6 million) collaborations lead UK research community's response to H1N1 pandemic 4Carnegie Mellon researchers to develop probes to study cellular GPS 2Ancient penguin DNA raises doubts about accuracy of genetic dating techniques 2
... with a modular approach to instrument control, ... Plus NDS family provides modular software components ... management, giving you the flexibility to choose ... now and that can grow as your ...
... Workgroup solution is a highly scalable ... expression data in a workgroup or ... in over 40 leading pharmaceutical, biotechnology, ... GeneSpring Workgroup streamlines genomics research at ...
... designed for proteomic scale kinase profiling, ... and drug discovery research built on ... on-chip synthesis platform. These microarrays are ... Protein Kinase Substrate - Peptide Microarray ...
... 18 amino acid synthetic peptide whose sequences are derived from mouse ... carboxy terminus): S(21) - S - M - P - L ... A - I - D - K - K - I ... peptide may be used for neutralization and control experiments with the ...
Biology Products: